

PROSPECTUS SUPPLEMENT NO. 1

(to Prospectus dated March 8, 2019)

REPRO MED SYSTEMS, INC.

11,101,697 shares of common stock

This prospectus supplement No. 1 supplements and amends the prospectus dated March 8, 2019 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-229498). This prospectus supplement is being filed to update and supplement the information in the Prospectus with information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 26, 2019 (the “Current Report”). Accordingly, we have attached the Current Report to this prospectus supplement.

The Prospectus and this prospectus supplement relate solely to 11,101,697 shares of REPRO MED SYSTEMS, INC. common stock, par value \$0.01 per share, which we refer to as our common stock, which may be offered for sale from time to time by the stockholders named under the heading “Selling Stockholders” in the Prospectus.

This prospectus supplement should be read in conjunction with the Prospectus, including any supplements or amendments thereto. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements to it.

Our common stock is currently listed on the OTCQX under the symbol “REPR.” The closing price of our common stock as reported on the OTCQX on April 25, 2019, was \$1.63.

**Investing in our common stock involves risks, and you should not invest unless you can afford to lose your entire investment. See the section entitled “Risk Factors” beginning on page 5 of the Prospectus.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

**The date of this prospectus supplement is April 29, 2019.**

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) April 23, 2019

**REPRO MED SYSTEMS, INC.**

(Exact name of registrant as specified in its charter)

**New York**  
(State or other jurisdiction  
of incorporation)

**0-12305**  
(Commission  
File Number)

**13-3044880**  
(IRS Employer  
Identification No.)

**24 Carpenter Road, Chester, New York**  
(Address of principal executive offices)

**10918**  
(Zip Code)

Registrant's telephone number, including area code **(845) 469-2042**

not applicable  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**ITEM 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS**

Set forth below are the final voting results from the 2019 Annual Meeting of Shareholders of Repro Med Systems, Inc. (the “Company”) held on April 23, 2019: For more information on the following proposals, see the Company’s proxy statement for the 2019 Annual Meeting of Shareholders, filed with the Securities and Exchange Commission on March 8, 2019.

**PROPOSAL 1: ELECTION OF DIRECTORS**

The nominees for director set forth under “Nominees” below were elected to the Company’s board of directors.

NOMINEES	NUMBER OF SHARES		
	FOR	WITHHELD	BROKER NON-VOTE
Daniel S. Goldberger	24,851,975	87,554	8,842,600
Arthur J. Radin	24,851,975	87,554	8,842,600
David W. Anderson	24,851,975	87,554	8,842,600
Joseph M. Manko, Jr.	23,952,275	987,254	8,842,600
Robert T. Allen	24,851,975	87,554	8,842,600
James M. Beck	24,851,975	87,554	8,842,600
Kathy S. Frommer	24,851,975	87,554	8,842,600

**PROPOSAL 2: ADVISORY VOTE - EXECUTIVE COMPENSATION**

The Company’s shareholders approved, on an advisory basis, the compensation of the Company’s named executive officers.

	FOR	AGAINST	ABSTAIN	BROKER NON-VOTE
Number of Shares	23,698,056	126,423	1,115,050	8,842,600

**PROPOSAL 3: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS**

The Company’s shareholders ratified the appointment of McGrail Merkel Quinn & Associates, P.C. as the Company’s independent registered public accountants for the 2019 fiscal year.

	FOR	AGAINST	ABSTAIN
Number of Shares	33,466,289	39,232	276,608

**PROPOSAL 4: APPROVAL, ON AN ADVISORY BASIS, OF THE FREQUENCY OF FUTURE VOTES ON EXECUTIVE COMPENSATION**

The Company’s shareholders approved, on an advisory basis, the frequency of future advisory votes on executive compensation of One Year. In light of such vote, the Company will include a shareholder vote on executive compensation in its proxy materials each year.

	1 YEAR	2 YEARS	3 YEARS	ABSTAIN	BROKER NON-VOTE
Number of Shares	23,607,684	325,676	83,619	922,550	8,842,600

**PROPOSAL 5: APPROVAL TO INCREASE THE MAXIMUM NUMBER OF SHARES THAT MAY BE AWARDED UNDER THE 2015 STOCK OPTION PLAN**

The Company’s shareholders approved to increase the maximum number of shares that may be awarded under the 2015 Stock Option Plan from 4,000,000 to 6,000,000.

	FOR	AGAINST	ABSTAIN	BROKER NON-VOTE
Number of Shares	23,291,537	1,514,117	131,875	8,842,600

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REPRO MED SYSTEMS, INC.  
(Registrant)

Date: April 26, 2019

By: /s/ Karen Fisher  
Karen Fisher  
Chief Financial Officer